Ardelyx, Inc. (FRA:41X)

Germany · Delayed Price · Currency is EUR

5.06

-0.70 (-12.16%)

At close: Feb 20, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development and Commercialization of Biopharmaceutical Products	407.32M	333.62M	124.46M	52.16M	10.10M
Development and Commercialization of Biopharmaceutical Products Growth	22.09%	168.06%	138.61%	416.57%	33.36%
Total	407.32M	333.62M	124.46M	52.16M	10.10M
Total Growth	22.09%	168.06%	138.61%	416.57%	33.36%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	377.81M	319.20M	83.28M	15.60M	-
United States Growth	18.36%	283.30%	433.82%	-	-
Asia Pacific	29.17M	14.34M	41.12M	36.53M	10.08M
Asia Pacific Growth	103.40%	-65.12%	12.58%	262.23%	49.06%
North America	342.00K	78.00K	59.00K	31.00K	13.00K
North America Growth	338.46%	32.20%	90.32%	138.46%	-98.39%
Total	407.32M	333.62M	124.46M	52.16M	10.10M
Total Growth	22.09%	168.06%	138.61%	416.57%	33.36%

Source: S&P Global Market Intelligence.